American Association for Cancer Research (AACR), 2023.
سنة النشر:
2023
الوصف:
Supplementary Methods - construction of plasmids, synthesis of siRNA, and methods for RT-qPCR. Supplementary Figure Legends - legends for supplementary figures. Supplementary References - references for supplementary methods. Supplementary Figures (S1-S7) - S1 shows control experiments for TIFA phosphorylation by Aurora A (A-C), and TIFA interaction with Aurora A (D-E). S2 shows western blot analysis of PBMCs from AML patients and normal donors (A-B), and Pearson's correlation coefficient among TIFA, Aurora A, and NF-κB signaling factors (C). S3 shows that TIFA silencing (A) attenuated cell viabilities (B-C) and enhanced chemotoxicities (D-I) of leukemic lines. S4 shows that TIFA silencing enhanced chemotoxicities of AML PBMCs (A-C) via promotion of apoptosis (D-F). S5 shows that TIFA is a therapeutic target to enhance chemotherapeutic drug treatments. S6 shows that anti-inflammatory drugs enhanced effects of cytarabine treatment in vitro and in vivo (A-B and D), and the control experiments for figure 6D and 6E in the main text (C and E, respectively). S7 shows the schematic model of the functional role of TIFA in supporting leukemic cell growth and chemoresistance. Supplementary Tables (S1-S7) - S1 shows clinical manifestations of AML patients with higher and lower BM TIFA expression. S2 shows comparison of immune phenotypes of leukemia cells between AML patients with higher and lower BM TIFA expression. S3-5 show IC50 values of drugs for AML lines (S3), ALL and CML lines (S4), and AML patient PBMCs (S5) upon silencing of TIFA. S6-7 show IC50 values of drugs for AML
